Literature DB >> 11845002

Genetic risk factors for chronic obstructive pulmonary disease.

Andrew J Sandford1, Ladina Joos, Peter D Paré.   

Abstract

Cigarette smoking is clearly the major risk factor for chronic obstructive pulmonary disease. However, only a minority of cigarette smokers develops chronic obstructive pulmonary disease, indicating that other factors are involved. Family and twin studies suggest that at least some of those factors are genetic. This article reviews the genes investigated as potential risk factors for this disease, focusing on the recent literature. The only established genetic risk factor for chronic obstructive pulmonary disease is homozygosity for the Z allele of the alpha1 -antitrypsin gene. There is increasing evidence that heterozygotes for the Z allele may also be at increased risk. Variants in genes involved in xenobiotic metabolism, antioxidation, and the inflammatory response have also been associated with chronic obstructive pulmonary disease. Thus, the genetic basis for chronic obstructive pulmonary disease has begun to be elucidated, and it is likely that several genes will be implicated in the pathogenesis of this disease.

Entities:  

Mesh:

Year:  2002        PMID: 11845002     DOI: 10.1097/00063198-200203000-00002

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  14 in total

Review 1.  Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema.

Authors:  Stephen I Rennard; Shinsaku Togo; Olaf Holz
Journal:  Proc Am Thorac Soc       Date:  2006-11

Review 2.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

3.  Natural histories of chronic obstructive pulmonary disease.

Authors:  Stephen I Rennard; Jørgen Vestbo
Journal:  Proc Am Thorac Soc       Date:  2008-12-15

Review 4.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.

Authors:  H Clark; K Reid
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

6.  Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control study.

Authors:  Andras Penyige; Szilard Poliska; Eszter Csanky; Beata Scholtz; Balazs Dezso; Ivan Schmelczer; Iain Kilty; Laszlo Takacs; Laszlo Nagy
Journal:  BMC Med Genet       Date:  2010-11-02       Impact factor: 2.103

7.  The association of SERPINE2 gene with COPD in a Chinese Han population.

Authors:  Aihua Wang; Yingqiu Yin; Ping Chen; Qiji Liu; Qinfeng Yu; Wei Xiao
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

Review 8.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

9.  Association of the TLR4 Asp299Gly polymorphism with lung function in relation to body mass index.

Authors:  Punam Pahwa; Chandima P Karunanayake; Donna C Rennie; Yue Chen; David A Schwartz; James A Dosman
Journal:  BMC Pulm Med       Date:  2009-09-21       Impact factor: 3.317

10.  Genotypes in matrix metalloproteinase 9 are a risk factor for COPD.

Authors:  Yohannes Tesfaigzi; Orrin B Myers; Christine A Stidley; Kurt Schwalm; Maria Picchi; Richard E Crowell; Frank D Gilliland; Steven A Belinsky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.